Career and experience
Simon brings more than 25 years’ of experience across medical devices, pharmaceuticals and diagnostics, including wound management. Importantly, he is a purpose-driven and accomplished business leader who has successfully managed large, global commercial organisations with full P&L responsibility while growing business and earning market share.
Prior to joining Smith+Nephew, Simon was Group Vice President of Dentsply Sirona’s Dental Implant Global Business Unit. Prior to this Simon was Vice President, US Commercial Infectious Diseases including corporate accounts at Abbott Laboratories.
Simon joined Abbott following the acquisition of Alere Inc., where he had three successful years as the President of Latin America.
Prior to these roles, Simon had a 15-year career with Johnson & Johnson, where he held increasingly senior commercial roles spanning surgical devices, wound management, implants and pharmaceuticals including both global strategic marketing and P&L responsibilities.
Nationality
American/Canadian
Burn wound management Burn wounds are a global public health problem and a leading cause of morbidity, including prolonged hospitalisation, disfigurement and disability – often accompanied by stigma and social rejection.1 Our aim is to help mitigate the complications associated with burn wounds.
Pressure injury prevention Trusted to reduce the incidence of pressure injuries when used as part of a comprehensive prevention program, compared to standard care alone.1-3
Partial-thickness rotator cuff tears Partial-thickness tears can have a lasting impact on pain and shoulder function. When used in isolated bioinductive repair, the REGENETEN◊ Bioinductive Implant leads to tendon healing without the need for sutured repair;1-4 offering patients a faster recovery and return to activity than sutured repairs.4,5
Chondral and osteochondral knee repair Treat knee cartilage lesions and osteochondral defects in a single-stage procedure, even in the presence of mild to moderate osteoarthritis (Kellgren-Lawrence 0-3),1,2 with the porous, biocompatible CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant; shown to be clinically superior to the current surgical standard of care in level 1 clinical data.*1,2
